UroAlert - GU Oncology Daily

May 29, 2026

Videos

Peer-to-Peer Clinical Conversations

Selecting Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Multi-Step Approach - Pedro Barata

Pedro Barata discusses therapy selection and patient goals in metastatic hormone-sensitive prostate cancer.

View

Investigating Pembrolizumab Alone with Response-Guided Bladder Sparing in MIBC - Matthew Galsky

Matthew Galsky

Matthew Galsky presents HCRN GU 20-444, which enrolled 46 cisplatin-ineligible patients with T2-T3 N0 M0 muscle-invasive bladder cancer receiving two doses of pembrolizumab at six-week intervals.

View

Beyond the Abstracts

Pembrolizumab in Combination with Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial - Beyond the Abstract

Cambridge kidney One-Stop Mass Investigation Clinic (CkOSMIC): A Nonrandomised Feasibility Study - Beyond the Abstract

Conference Coverage

AUA 2026: Association of Serum Kidney Injury Molecule-1 (KIM-1) with Treatment Response and Survival in Metastatic Renal Cell Carcinoma

AUA 2026: Practice-changing, Paradigm-shifting Clinical Trials in Urology: Intravenous Pembrolizumab Combined with Intravesical BCG for Patients with BCG-Naïve “Very High-Risk” T1 NMIBC

AUA 2026: Practice-Changing, Paradigm-Shifting Clinical Trials in Urology: Durvalumab with BCG Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer: Expanded Efficacy and Safety Analyses from POTOMAC

AUA 2026: Practice-Changing, Paradigm-Shifting Clinical Trials in Urology: A Non-Viral Intravesical Gene Therapy for BCG-Unresponsive NMIBC with CIS, with or Without Papillary Disease: Pivotal Phase 2 Interim Results of Detalimogene Voraplasmid

AUA 2026: Practice-Changing, Paradigm-Shifting Clinical Trials in Urology: Darolutamide + ADT in mHSPC: ARASEC – US Prospective, Open-Label Phase 2 Study with an External Control

Articles

Editor Selected Abstracts and Commentaries

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

UroAlert - GU Oncology Daily

Bladder Cancer

Penile & Urethral Cancers

Renal Cancer

Prostate Cancer

Upper Tract Tumors

Login